Application of Cancer Organoid Model for Drug Screening and Personalized Therapy

Drug screening—i.e., testing the effects of a number of drugs in multiple cell lines—is used for drug discovery and development, and can also be performed to evaluate the heterogeneity of a disease entity. Notably, intertumoral heterogeneity is a large hurdle to overcome for esta...

Full description

Bibliographic Details
Main Authors: Jumpei Kondo, Masahiro Inoue
Format: Article
Language:English
Published: MDPI AG 2019-05-01
Series:Cells
Subjects:
Online Access:https://www.mdpi.com/2073-4409/8/5/470
id doaj-ad0537bcd21948918fa235905e19fb6f
record_format Article
spelling doaj-ad0537bcd21948918fa235905e19fb6f2020-11-24T20:43:08ZengMDPI AGCells2073-44092019-05-018547010.3390/cells8050470cells8050470Application of Cancer Organoid Model for Drug Screening and Personalized TherapyJumpei Kondo0Masahiro Inoue1Department of Clinical Bio-resource Research and Development, Graduate School of Medicine Kyoto University, Kyoto 606-8501, JapanDepartment of Clinical Bio-resource Research and Development, Graduate School of Medicine Kyoto University, Kyoto 606-8501, JapanDrug screening—i.e., testing the effects of a number of drugs in multiple cell lines—is used for drug discovery and development, and can also be performed to evaluate the heterogeneity of a disease entity. Notably, intertumoral heterogeneity is a large hurdle to overcome for establishing standard cancer treatment, necessitating disease models better than conventional established 2D cell lines for screening novel treatment candidates. In the present review, we outline recent progress regarding experimental cancer models having more physiological and clinical relevance for drug screening, which are important for the successful evaluation of cellular response to drugs. The review is particularly focused on drug screening using the cancer organoid model, which is emerging as a better physiological disease model than conventional established 2D cell lines. We also review the use of cancer organoids to examine intertumor and intratumor heterogeneity, and introduce the perspective of the clinical use of cancer organoids to enable precision medicine.https://www.mdpi.com/2073-4409/8/5/470drug screeningcancercell linesorganoidspheroidheterogeneityprecision medicine
collection DOAJ
language English
format Article
sources DOAJ
author Jumpei Kondo
Masahiro Inoue
spellingShingle Jumpei Kondo
Masahiro Inoue
Application of Cancer Organoid Model for Drug Screening and Personalized Therapy
Cells
drug screening
cancer
cell lines
organoid
spheroid
heterogeneity
precision medicine
author_facet Jumpei Kondo
Masahiro Inoue
author_sort Jumpei Kondo
title Application of Cancer Organoid Model for Drug Screening and Personalized Therapy
title_short Application of Cancer Organoid Model for Drug Screening and Personalized Therapy
title_full Application of Cancer Organoid Model for Drug Screening and Personalized Therapy
title_fullStr Application of Cancer Organoid Model for Drug Screening and Personalized Therapy
title_full_unstemmed Application of Cancer Organoid Model for Drug Screening and Personalized Therapy
title_sort application of cancer organoid model for drug screening and personalized therapy
publisher MDPI AG
series Cells
issn 2073-4409
publishDate 2019-05-01
description Drug screening—i.e., testing the effects of a number of drugs in multiple cell lines—is used for drug discovery and development, and can also be performed to evaluate the heterogeneity of a disease entity. Notably, intertumoral heterogeneity is a large hurdle to overcome for establishing standard cancer treatment, necessitating disease models better than conventional established 2D cell lines for screening novel treatment candidates. In the present review, we outline recent progress regarding experimental cancer models having more physiological and clinical relevance for drug screening, which are important for the successful evaluation of cellular response to drugs. The review is particularly focused on drug screening using the cancer organoid model, which is emerging as a better physiological disease model than conventional established 2D cell lines. We also review the use of cancer organoids to examine intertumor and intratumor heterogeneity, and introduce the perspective of the clinical use of cancer organoids to enable precision medicine.
topic drug screening
cancer
cell lines
organoid
spheroid
heterogeneity
precision medicine
url https://www.mdpi.com/2073-4409/8/5/470
work_keys_str_mv AT jumpeikondo applicationofcancerorganoidmodelfordrugscreeningandpersonalizedtherapy
AT masahiroinoue applicationofcancerorganoidmodelfordrugscreeningandpersonalizedtherapy
_version_ 1716820448098910208